<DOC>
	<DOCNO>NCT02988466</DOCNO>
	<brief_summary>This single institution phase II study reduce intensity conditioning ( RIC ) follow haploidentical hematopoietic cell transplant ( haplo-HCT ) person diagnosis hematologic malignancy . Conditioning consist fludarabine , cyclophosphamide , melphalan total body irradiation ( TBI ) preparative regimen melphalan dose reduction patient ≥55 year old HCT Comorbidity Index ( CI ) &gt; 3 . This study use two-stage phase II design accrual goal 44 patient , use 22 patient separately arm A B .</brief_summary>
	<brief_title>Reduced Intensity ( RIC ) Conditioning And Transplantation HLA-Haploidentical Related Hematopoietic</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Karnofsky performance status ≥70 % Lansky play score ≥ 70 % A related haploidentical bone marrow donor 2 3 HLA locusmismatches The donor recipient must HLA identical least one haplotype ( use high resolution DNA base type ) follow genetic locus : HLAA , HLAB , HLAC , HLADRB1 . Adequate liver renal function Absence decompensated congestive heart failure , uncontrolled arrhythmia leave ventricular ejection fraction ≥ 40 % Diffusion capacity correct ( DLCOcorr ) &gt; 40 % predict , absence O2 requirement &gt; 6 month prior autologous transplant ( applicable ) Agrees use contraception study treatment Voluntary write consent ( adult parent/guardian presentation minor information sheet , appropriate ) &lt; 70 year available 56/6 HLAA , B , DRB1 match sibling donor Pregnancy breastfeed Evidence HIV infection know HIV positive serology Current active uncontrolled serious infection Acute leukemia morphologic relapse/persistent disease define &gt; 5 % blast normocellular bone marrow OR % blast blast unique morphologic marker ( e.g . Auer rod ) . CML blast crisis Large cell lymphoma , mantle cell lymphoma Hodgkin disease progressive salvage therapy . stable nonbulky disease acceptable . Active central nervous system malignancy Criteria For Donor Selection : Donors must HLAhaploidentical relatives patient , define share HLA haplotype donor patient HLAA , B , C , DRB1 . Eligible donor ( 1470 year old ) include biological child , sibling half sibling , parent , able willing undergo bone marrow harvesting . For donor &lt; 18 year , maximum recipient weight ( actual body weight ) exceed 1.25 time donor weight ( actual body weight ) 1 In addition , bone marrow product volume limit 20 ml/kg donor weight donor &lt; 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute Leukemias</keyword>
	<keyword>Acute myeloid leukemia ( AML )</keyword>
	<keyword>Acute lymphoblastic leukemia ( ALL ) /lymphoma</keyword>
	<keyword>Biphenotypic/Undifferentiated/Prolymphocytic Leukemias</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Chronic myelogenous leukemia</keyword>
	<keyword>Minimal Residual Disease ( MRD ) positive leukemia</keyword>
	<keyword>Leukemia Myelodysplastic Syndromes ( MDS ) aplasia</keyword>
	<keyword>Myeloproliferative neoplasms/myelofibrosis</keyword>
	<keyword>Relapsed large-cell lymphoma , mantle-cell lymphoma Hodgkin lymphoma</keyword>
	<keyword>Burkitt 's lymphoma</keyword>
	<keyword>Relapsed T-cell lymphoma</keyword>
	<keyword>Natural Killer cell malignancy</keyword>
	<keyword>Relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , marginal zone B-cell lymphoma , follicular lymphoma</keyword>
	<keyword>Lymphoplasmacytic lymphoma</keyword>
	<keyword>Relapsed multiple myeloma</keyword>
	<keyword>Bone marrow failure syndrome</keyword>
</DOC>